Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-21 English
10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
Regulatory Filings
2026-05-13 English
SCHEDULE 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
Major Shareholding Notification
2026-03-30 English
8-K Filing
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 11, 2026. It announces that the company, Protalix BioTherapeutics, has posted a corporate presentation to its website and furnishes a copy of this presentation as Exhibit 99.1. The text explicitly states this is a Regulation FD Disclosure and that the presentation is furnished as an exhibit, not the report itself. The document length is 3715 characters, which is relatively short and consistent with an announcement rather than a full report. There are no financial statements or substantive financial data included in the text. Therefore, this document is best classified as an Investor Presentation (IP) filing type, as it relates to a corporate presentation provided to investors.
2026-02-11 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports an event dated January 30, 2026, specifically a press release about a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding a dosing regimen approval. The document includes a press release as an exhibit and does not contain financial statements or detailed financial data. Form 8-K filings are regulatory filings used to report significant events and are not annual or quarterly reports, audit reports, or earnings releases. Given the nature of the content and the form type, the appropriate classification is Regulatory Filings (RNS). The document length is 4129 characters, which is relatively short and consistent with a regulatory announcement rather than a full report.
2026-01-30 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.